MSCs-DERIVED EVS AS POTENTIAL TREATMENT IN A PHENCYCLIDINE MODEL OF SCHIZOPHRENIA

ConclusionIn this study, we assessed the feasibility of intranasal delivery of MSCs-derived EVs to improve the positive and negative symptoms in a PCP model of schizophrenia. Our results show that mice treated with MSCs-EVs are beneficial for preventing both positive and negative symptoms in a PCP-model of schizophrenia. While PCP-treated mice showed a deficiency in social interaction and increased vulnerability to amphetamine, mice co-administered with PCP and MSCs-EVs behaved similarly to the sham group, treated with saline. Immunohistochemical studies demonstrated that the EVs prevented loss of Paravalbumin-expressing GABAergic neurons in the PFC of treated mice, where EVs were most congregated.We believe MSCs-derived EVs may be an invaluable treatment for schizophrenia. With the convenient intranasal administration and ability to arrive at the site of damage in the diseased brain, they may offer an unprecedented improvement in negative symptoms.
Source: Cytotherapy - Category: Cytology Source Type: research